osimertinib
astrazeneca
['sclc', 'nsclc', 'osimertinib']
#asco23 abs8508 neoadjuvant osimertinib in surgically resectable egfr-mutated nsclc phase ii trial. 15% major pathological response rate (mpr). treatment was safe with significant adverse events occurring in 3 patients. 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows @LungCancerRX https://t.co/dsiuV460lQ